The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator.

In fact, as many as 4 million American adults have treatment-resistant depression. And for them, well, ketamine might be the only drug out there that can provide relief. That's according to Doctor ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

Around that time, a doctor friend told him about ketamine for treatment-resistant depression. It wasn’t an FDA- approved treatment. But Winograd says it saved his life. But for every success s ...

The FDA will be working closely with us to expedite the development process and increase the chances of getting this treatment to people suffering with depression as quickly as possible.” ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...